Cancer BiologybioRxivPreprint
Second-Generation Cap Analogue Prodrugs for Targeting Aberrant Eukaryotic Translation Initiation Factor 4E (eIF4E) Activity in Drug-Resistant Melanoma
Emilio L. Cárdenas, Rachel L. O’Rourke, Arya Menon…·Amanda L. Garner
This study develops second-generation cap analogue inhibitors to target eIF4E-mediated cap-dependent translation in drug-resistant melanoma cells.
DOI 10.1101/2024.09.25.614990